Medtronic 2026 Conference Call Summary Company Overview - **Company**: Medtronic (NYSE: MDT) - **Date**: March 11, 2026 - **Key Speaker**: Thierry Piéton, CFO Industry Insights - **Market Dynamics**: The overall market for the CAS (Cardiac Ablation Systems) was valued at $13 billion, growing at 20% in Q3 2026, with expectations to continue growing in the high teens into 2027 [doc id='24']. Key Points and Arguments Business Evolution and Growth - **Recent Developments**: Medtronic has seen significant changes over the past year, including new product launches, portfolio actions, and a focus on M&A activities [doc id='5'][doc id='6']. - **Growth Confidence**: The company is experiencing improved performance, with organic growth expected to exceed 5.5% in fiscal year 2026, driven by the acceleration of the CAS business [doc id='16']. M&A Activity - **Scientia Acquisition**: The acquisition of Scientia is viewed as a strategic fit, enhancing Medtronic's capabilities in stroke treatment with a differentiated access guidewire [doc id='10'][doc id='13']. - **Future M&A Strategy**: Medtronic aims for medium-sized tuck-in acquisitions, focusing on deals that create synergies and enhance product ecosystems [doc id='89']. Financial Guidance - **EPS Growth**: Medtronic is committing to high single-digit EPS growth for the next year, despite some dilution from recent M&A activities [doc id='20']. - **Gross Margins**: Improvements in gross margins are anticipated due to operational efficiencies and better product mix [doc id='18']. Product Innovations - **CAS Business**: The CAS business has shown strong momentum, with a unique offering (Sphere-9) that integrates multiple technologies, leading to increased physician adoption [doc id='24'][doc id='25']. - **Renal Denervation**: Early demand for the renal denervation business is strong, with significant interest in the procedure, although reimbursement remains a challenge [doc id='40'][doc id='41']. - **TAVR Challenges**: The TAVR business has faced competitive pressures, but Medtronic remains optimistic about its market position and ongoing product improvements [doc id='50'][doc id='52']. Competitive Landscape - **Hypertension Treatment**: Medtronic's Simplicity therapy shows long-term benefits for hypertension, contrasting with competitors' products that do not maintain efficacy over time [doc id='46']. - **Neurovascular Innovations**: The Altaviva product is expected to significantly contribute to growth, with a large potential patient base [doc id='60']. Future Outlook - **MiniMed Separation**: The separation of the MiniMed business is progressing, with expectations for it to be accretive to Medtronic's EPS in the long term [doc id='83']. - **Hugo Robotics**: The Hugo robotic system is now FDA approved, enhancing Medtronic's offerings in the surgical space and expected to improve hospital workflows [doc id='73']. Additional Important Insights - **Market Penetration**: Current market penetration for PFA (Pulmonary Vein Ablation) is estimated at 50%-60%, with potential to reach 80% in the coming years [doc id='30']. - **Stealth Access Platform**: The integration of navigation and robotic assistance in the Stealth Access platform is expected to improve patient outcomes and enhance market competitiveness [doc id='68']. This summary encapsulates the key insights and strategic directions discussed during the Medtronic conference call, highlighting the company's growth trajectory, product innovations, and market positioning.

Core Insights - Medtronic reported total revenue of $9 billion in Q3 FY26, marking an 8.7% year-over-year increase, driven by significant growth in its cardiovascular portfolio [1][5] - The company anticipates organic revenue growth of approximately 5.5% for FY26, with earnings projected in the range of $5.62 to $5.66 per share [1] Cardiovascular Portfolio Performance - The cardiovascular portfolio generated $3.46 billion in revenue for Q3, reflecting a 13.8% year-over-year increase, with the cardiac ablation segment growing 80% year-over-year [3][4] - The PulseSelect pulsed-field ablation (PFA) system was a key contributor, accounting for 80% of the cardiac ablation revenue [3] - Overall, the cardiovascular portfolio achieved its strongest growth in the last decade, excluding COVID-19 comparisons, with cardiac rhythm management contributing 15% of total revenue and growing by 5% [4] Analyst Insights - Analyst Brandon Vasquez from William Blair noted that Q3 sales exceeded Wall Street estimates by 1%, indicating positive momentum in Medtronic's growth drivers [2] Neuroscience Portfolio Performance - Medtronic's neuroscience portfolio grew by 4.1% year-over-year to $2.56 billion, although this growth was slightly below expectations for Q3 [6] FDA Approval and Market Opportunities - The company received FDA approval for Altaviva, an implantable tibial nerve stimulation system, which is expected to tap into a billion-dollar market opportunity [7]

Core Insights - Medtronic has launched a direct-to-consumer "Go Beyond" campaign, resulting in a significant increase in website traffic, with visits rising from approximately 50,000 to 2.5 million [1] - The company is focusing on scaling its Symplicity platform for renal denervation, targeting the 18 million patients in the U.S. with uncontrolled hypertension [2] - Medtronic's management highlighted strong growth in various product areas, including cardiovascular and diabetes segments, while reiterating financial guidance for fiscal 2026 and expectations for high single-digit adjusted EPS growth in fiscal 2027 [4][5] Product and Market Developments - The cardiovascular portfolio revenue grew 11% year-over-year, with a notable 80% growth in cardiac ablation systems (CAS), driven by pulsed field ablation (PFA) [12] - The MiniMed diabetes business reported a 15% increase in revenue, with significant growth attributed to international markets and new product launches [16] - Medtronic is scaling its Symplicity Spyral and Altaviva platforms, with early traction observed in patient referrals and physician training [6] Financial Performance - Medtronic reported revenue of $9.0 billion for the quarter, reflecting an 8.7% increase, with adjusted gross margin at 64.9% [5][17] - Adjusted operating profit reached $2.2 billion, with an adjusted operating margin of 24.1%, exceeding expectations [18] - The company maintained its fiscal 2026 organic revenue growth guidance of approximately 5.5% and adjusted EPS guidance of $5.62 to $5.66 [19] Regulatory and Technological Advancements - The Hugo robotic-assisted surgery system received FDA clearance for urologic procedures, marking the beginning of its U.S. launch [7] - The Stealth Access Surgical System for spinal procedures was also cleared by the FDA, integrating AI-powered planning and robotics [10][11] - Medtronic's Touch Surgery digital ecosystem installations surpassed 1,000 globally, showcasing a 20% sequential growth [8]

Core Insights - The company experienced its strongest growth in the Cardiovascular portfolio in 10 years, achieving an 11% increase, primarily due to the rapid adoption of Pulse Field Ablation (PFA) [1] - Cardiac Ablation Solutions (CAS) saw an 80% growth attributed to the successful launch of the Affera mapping and navigation system and Sphere-9 catheter [1] - The company is shifting from foundational market-building to active commercial scaling for the Symplicity Spyral hypertension treatment and Altaviva for incontinence [1] - Strategic positioning in the spine market is being enhanced by the Stealth AXiS platform, which integrates AI-powered planning and robotics into existing surgical workflows [1] - A 30-basis-point benefit from pricing helped to mitigate negative impacts from inflation, prior-year non-recurring items, and a 20-basis-point headwind from cost-efficiency programs [1] - The Diabetes business experienced accelerated growth in the U.S. following the launch of Simplera Sync and Instinct, supported by expanded pharmacy channel access for the 780G system [1]

Financial Data and Key Metrics Changes - The company reported revenue of $9 billion, reflecting an 8.7% increase year-over-year and a 6% organic growth, which is a 50 basis point acceleration from the previous quarter [18][19] - Adjusted gross margin was 64.9%, ahead of expectations, with a 30 basis point benefit from pricing [19][20] - Adjusted operating profit was $2.2 billion, resulting in an adjusted operating margin of 24.1%, also ahead of expectations [21] Business Line Data and Key Metrics Changes - The cardiovascular portfolio delivered 11% year-over-year revenue growth, with 13% growth in the U.S., marking the strongest growth in the last 10 years, excluding COVID comparisons [12] - Cardiac rhythm management (CRM) contributed 15% of total revenue and grew 5%, driven by double-digit growth in Micra and over 70% growth in Aurora EV-ICD [12][13] - The neuroscience portfolio grew 3%, with expectations for the pipeline to impact growth in the fourth quarter [14][15] Market Data and Key Metrics Changes - U.S. growth was 6% year-over-year, the strongest performance since fiscal year 2019, excluding COVID comparisons [19] - In China, low single-digit growth was reported while navigating volume-based procurement challenges [19] - Western Europe experienced high single-digit growth, contributing to balanced geographical performance [19] Company Strategy and Development Direction - The company is focused on expanding its innovation pipeline, particularly in high-growth areas such as hypertension treatment with Symplicity and urinary incontinence with Altaviva [2][3] - The launch of the Hugo robotic system is seen as a significant growth driver, with initial installations and positive feedback from early cases [5][6] - The company is committed to M&A strategies, focusing on tuck-in deals that align with existing business segments [59][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining revenue and earnings growth, highlighting strong contributors like CAS and CRM [10][24] - The company anticipates continued growth from new product launches and market expansions, particularly in the U.S. [10][39] - There is an expectation for high single-digit EPS growth in fiscal year 2027, despite some headwinds from tariffs and M&A activities [24][68] Other Important Information - The planned separation of the MiniMed diabetes business is on track, with expectations for completion by the end of calendar year 2026 [18] - The company is investing in R&D and marketing to support growth areas, particularly in renal denervation and Altaviva [66] Q&A Session Summary Question: Comments on accelerating revenue growth next year and high single-digit earnings growth - Management indicated that growth will continue, driven by strong performance in CAS and other growth drivers like Symplicity and Altaviva [30][39] Question: Monitoring progress for RDN and Altaviva - Management mentioned strong leading indicators, including training of over 500 physicians and opening of new accounts for RDN [43] Question: Thoughts on capital allocation and M&A strategy - The company is focused on tuck-in M&A opportunities that align with existing business segments, prioritizing high-growth areas [59][60] Question: Impact of Hugo on surgical business growth - Management expressed excitement about the Hugo system's potential, noting positive feedback from initial cases and strong leading indicators [87]

Core Insights - Medtronic is positioned to accelerate revenue and earnings growth through engineering, manufacturing, and regulatory expertise [1][2] - The company is focusing on generational growth drivers and a continuous pipeline of new technologies in various medical fields [1] - Medtronic aims to expand margins to increase R&D investment and enhance EPS leverage [2] - Strategic portfolio management and capital allocation are key components of the company's growth strategy [2]

Core Insights - Intuitive Surgical (ISRG) is experiencing a decline in U.S. bariatric surgery volumes, attributed to the rapid adoption of GLP-1 weight-loss drugs, with six consecutive quarters of high single-digit declines [1][10] - Bariatric procedures now account for less than 3% of U.S. da Vinci procedures, and the decline shows no signs of stabilization [2][10] - Despite the challenges in bariatric surgery, Intuitive Surgical is seeing growth in other areas, particularly benign general surgery, which includes procedures like cholecystectomy and hernia repair [3][10] Bariatric Surgery Impact - The ongoing decline in bariatric surgery volumes is linked to mixed patient behaviors regarding GLP-1 therapies, with some patients discontinuing due to costs or side effects [2] - Surgeons report uncertainty in predicting when bariatric procedure volumes may stabilize, indicating a challenging environment for the company [2] Growth in Other Areas - Intuitive Surgical is offsetting the decline in bariatric procedures with strong growth in benign general surgery, which is supported by the adoption of the da Vinci 5 platform that enhances efficiency and utilization rates [3][4] - International markets are also contributing positively, with general surgery and other procedures growing between 26% to 39% year-over-year outside the U.S. [5] Competitive Landscape - Other medical-device companies, such as Medtronic and Teleflex, are similarly affected by the rise of GLP-1 drugs impacting bariatric procedures, but they view this as a near-term challenge rather than a complete replacement of surgical options [7][10] - Medtronic is focusing on faster-growing segments to mitigate the impact of declining bariatric volumes, with significant growth in cardiac ablation and other areas [9] Financial Performance - Intuitive Surgical's shares have increased by 6.5% year-to-date, outperforming the industry average of 2% [13] - The company has a forward price-to-earnings ratio of 58.42, which is above the industry average but lower than its five-year median of 71.54 [14] - The Zacks Consensus Estimate indicates a projected earnings growth of 17.3% for 2025 compared to the previous year [15]

Core Insights - Medtronic has recently secured FDA approval for its Altaviva device on September 18, marking a significant milestone for the company [1]. Group 1 - Ryan Weispfenning, Vice President and Head of Investor Relations, hosted a call to showcase the Altaviva device [1]. - The event included a reminder that it would be recorded and available for replay on the company's website [2]. - Emily Elswick, President of the Pelvic Health business, was introduced as a special guest to discuss the Altaviva device [3].

Core Viewpoint - Medtronic has successfully secured FDA approval for its Altaviva device on September 18, marking a significant milestone for the company in the pelvic health sector [1]. Group 1 - Ryan Weispfenning, Vice President and Head of Investor Relations, is leading the call to showcase the Altaviva device [1]. - The event is being recorded, and a replay will be available on the company's website shortly after the call [2]. - The call includes forward-looking statements and will have a Q&A session for analysts and investors [2]. Group 2 - Emily Elswick, President of the Pelvic Health business, is introduced as a special guest to discuss the Altaviva device [3]. - The Pelvic Health business is one of the five segments within Medtronic's neuroscience portfolio [3].

Core Viewpoint - Medtronic's Altaviva device has received FDA approval as the first implantable tibial nerve stimulation device for treating overactive bladder (OAB), specifically urgency urinary incontinence (UUI), offering a new treatment option for millions of patients suffering from this condition [2][12]. Group 1: Technology and Clinical Features - The Altaviva device is implanted through a small incision at the ankle, making it a minimally invasive procedure that does not require sedation or imaging guidance, thus simplifying the operation [3]. - The device is approximately the size of half a piece of gum and is implanted just above the subcutaneous fascia, ensuring it does not interfere with daily activities [5]. - Compared to traditional therapies, Altaviva offers low invasiveness and long-term efficacy, emphasizing "no daily maintenance," which reduces the burden on patients [7]. Group 2: Clinical Trial Data - The approval of Medtronic's Altaviva is based on a series of clinical studies, including the TITAN 2 pivotal trial (NCT05226286) and the TITAN 1 feasibility study (NCT04873271) [8][9]. - The mechanism of action involves delivering electrical pulses to stimulate the tibial nerve, helping restore nerve signal transmission between the bladder and the brain, thereby improving bladder control [10]. - The core evidence for FDA approval included data from 188 UUI patients, showing that at 6 months post-implantation, at least 50% of patients experienced a reduction in UUI episodes [11]. - Safety data reported five adverse events related to the device or procedure, with one severe case requiring device removal after six weeks [11]. Group 3: Market Overview - Urinary incontinence is a widespread health issue globally, significantly impacting patients' quality of life, with over 25 million adults in the U.S. affected, particularly women over 50 [13]. - The global urinary incontinence treatment device market was valued at approximately $3.1 to $3.8 billion in 2023, projected to reach $6 to $6.5 billion by 2032, with a compound annual growth rate (CAGR) of 8% to 11% [13]. - Sacral nerve stimulation (SNS) is currently the most common implantable therapy in this field, with a market size of around $1.6 billion in 2023, expected to grow at a CAGR exceeding 11% by 2030, particularly in the Asia-Pacific region [13]. Group 4: Product Structure and Regional Market - Among various treatment options, the urethral sling represents the largest revenue-generating product category, with a market size exceeding $1.5 billion in 2023 [14]. - The U.S. remains the largest single market for urinary incontinence treatments, projected to reach approximately $3.78 billion by 2025, while the Chinese market is also growing rapidly, expected to reach about $380 million by 2025, with a similar CAGR of around 11% [14]. Group 5: Industry Trends - The launch of Medtronic's Altaviva device reflects a shift in the urinary incontinence treatment landscape, moving from traditional sacral nerve stimulation to more targeted and compact implantable solutions, indicating a growing demand for "minimally invasive, long-lasting, and high-compliance" treatments [16]. - The significant unmet treatment needs among the large population of urinary incontinence patients are driving accelerated investments in this field, with Altaviva's approval reinforcing Medtronic's leadership in nerve modulation and setting a new direction for product iteration in the industry [16].